Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about $10 billion, its largest-ever deal, in a move to broaden beyond cystic fibrosis into specialty endocrinology. The acquisition includes Crinetics’ commercially launched Palsonify (paltusotine) for acromegaly and a late-stage pipeline asset, atumelnant, for congenital adrenal hyperplasia. Under the terms described by multiple outlets, Vertex will pay $85 per share in cash and aims to close the transaction in the third quarter of 2026. The company estimates combined peak sales potential of more than $5 billion for the two lead assets, positioning rare endocrine indications as a new commercial pillar. Analysts and investors will now focus on how quickly Vertex can scale Palsonify’s market footprint and support atumelnant’s path to potential label expansion, while integrating Crinetics’ endocrine development capabilities into Vertex’s broader commercialization infrastructure.